Marina Díaz Beyá

I am a senior hematologist with a consolidated clinical–translational research profile in myeloid malignancies. I work as an attending physician at Hospital línic de Barcelona and as a researcher at IDIBAPS, combining direct patient are with investigator-driven research addressing unmet diagnostic and herapeutic needs. I have served on two occasions as an expert evaluator in the Catalan rogramme for Pharmacotherapeutic Harmonization (CatSalut), contributing to he evaluation of gilteritinib for relapsed/refractory FLT3-mutated AML (2021) nd midostaurin for FLT3-mutated AML (2020), gaining experience in egulatory-level therapeutic assessment. I hold national leadership roles as a board member of the Spanish Group of Myelodysplastic Syndromes (GESMD), the Cooperative Group for the Stud